Back to Authors

Pearson, Sally‐Ann

https://orcid.org/0000-0002-7421-7195

Mayo Clinic

The Royal Melbourne Hospital

Citations 1

Family History of Colorectal Cancer in BRAF p.V600E-Mutated Colorectal Cancer Cases
Buchanan, Daniel D. , Win, Aung Ko , Walsh, Michael D. , Walters, Rhiannon, Nagler, Belinda, Pearson, Sally‐Ann , Parry, Susan, Arnold, Julie, Winship, Ingrid , Giles, Graham G. , Lindor, Noralane M. , Potter, John D. , Rosty, Christophe , Young, Joanne , Jenkins, Mark A. , Clendenning, Mark , Macrae, Finlay , Hopper, John L. , Buchanan, Daniel D , Win, Aung K , Giles, Graham G , Jenkins, Mark A , Potter, John D , Rosty, Christophe , Winship, Ingrid M

Cancer Epidemiology, Biomarkers & Prevention | March 6, 2013 | Volume: 22 | Issue: 5 | Pages: 917-926

10.1158/1055-9965.epi-12-1211 Get It

Abstract Background: Previous reports suggest that relatives of colorectal cancer (CRC)-affected probands carrying the BRAF p.V600E mutation are at an increased risk of CRC and extracolonic cancers (ECC). In this study, we estimated the association between a family history of either CRC or ECC and risk of CRC with a BRAF p.V600E mutation. Methods: Population-based CRC cases (probands, ages 18–59 years at diagnosis), recruited irrespective of family cancer history, were characterized for BRAF p.V600E mutation and mismatch repair (MMR) status. ORs and 95% confidence intervals (CI) were estimated using multivariable logistic regression. Results: The 690 eligible probands showed a mean age at CRC diagnosis of 46.9 ± 7.8 years, with 313 (47.9%) reporting a family history of CRC and 53 (7.7%) that were BRAF-mutated. Probands with BRAF-mutated, MMR-proficient CRCs were less likely to have a family history of CRC than probands that were BRAF wild-type (OR, 0.46; 95% CI, 0.24–0.91; P = 0.03). For probands with a BRAF-mutated CRC, the mean age at diagnosis was greater for those with a CRC-affected first- or second-degree relative (49.3 ± 6.4 years) compared with those without a family history (43.8 ± 10.2 years; P = 0.04). The older the age at diagnosis of CRC with the BRAF p.V600E mutation, the more likely these probands were to show a family history of CRC (OR, 1.09 per year of age; 95% CI, 1.00–1.18; P = 0.04). Conclusions: Probands with early-onset, BRAF-mutated, and MMR-proficient CRC were less likely to have a family history of CRC than probands that were BRAF-wild-type. Impact: These findings provide useful insights for cancer risk assessment in families and suggest that familial or inherited factors are more important in early-onset, BRAF-wild-type CRC. Cancer Epidemiol Biomarkers Prev; 22(5); 917–26. ©2013 AACR.